Insight

Nov 4, 2024, 12:24

Julian Downward: Mechanisms limiting responses of KRAS mutant lung cancer to KRAS inhibitors and immunotherapy

Julian Downward, Cancer biologist at the Francis Crick Institute, shared on X:

“In our new paper just out in Science Advances we investigate mechanisms that may be limiting responses of KRAS mutant lung cancer to KRAS inhibitors and immunotherapy.”

Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor–induced immune responses.

Authors: Megan Cole, Panayiotis Anastasiou, Claudia Lee, Xiaofei Yu, Andrea De Castro, Jannes Roelink, Chris Moore, Edurne Mugarza, Martin Jones, Karishma Valand, Sareena Rana, Emma Colliver, Mihaela Angelova, Katey S. S. Enfield, Alastair Magness, Asher Mullokandov, Gavin Kelly, Tanja D. De Gruijl, Miriam Molina-Arcas, Charles Swanton, Julian Downward, Febe Van Maldeghem.

Julian Downward

Alastair Magness Andrea De Castro Asher Mullokandov cancer Charles Swanton Chris Moore Claudia Lee Edurne Mugarza Emma Colliver Febe Van Maldeghem Gavin Kelly Jannes Roelink Julian Downward Karishma Valand Katey S. S. Enfield Martin Jones Megan Cole Mihaela Angelova Miriam Molina-Arcas OncoDaily Oncology Panayiotis Anastasiou Sareena Rana Tanja D. De Gruijl Xiaofei Yu

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology